Kymera Therapeutics Inc Ordinary Shares KYMR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KYMR is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $33.35
- Day Range
- $33.22–34.14
- 52-Week Range
- $9.60–45.31
- Bid/Ask
- $32.27 / $35.50
- Market Cap
- $2.05 Bil
- Volume/Avg
- 452,364 / 646,822
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 24.78
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 187
- Website
- https://www.kymeratx.com
Comparables
Valuation
|
Metric
|
KYMR
|
MRSN
|
PRLD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.70 | 9.42 | 0.94 |
Price/Sales | 24.78 | 9.07 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
KYMR
MRSN
PRLD
Financial Strength
|
Metric
|
KYMR
|
MRSN
|
PRLD
|
|---|---|---|---|
Quick Ratio | 4.59 | 3.29 | 10.67 |
Current Ratio | 4.73 | 3.36 | 10.79 |
Interest Coverage | −844.54 | −44.11 | — |
Quick Ratio
KYMR
MRSN
PRLD
Profitability
|
Metric
|
KYMR
|
MRSN
|
PRLD
|
|---|---|---|---|
Return on Assets (Normalized) | −18.63% | −49.57% | −38.93% |
Return on Equity (Normalized) | −25.04% | −211.52% | −43.41% |
Return on Invested Capital (Normalized) | −25.48% | −146.81% | −42.59% |
Return on Assets
KYMR
MRSN
PRLD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sqzfxwsc | Jxjs | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Prjppxsv | Wxwvy | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wgfkqwlyz | Vvkrjn | $97.8 Bil | |
MRNA
| Moderna Inc | Jcgnkbr | Lrrn | $41.3 Bil | |
ARGX
| argenx SE ADR | Hgbgzzrg | Vhl | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Jybrxvdn | Bkww | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bztvvzjp | Kwxkdl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hsrnbwds | Hnshmxb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yyffnqjhbf | Kzfym | $12.5 Bil | |
INCY
| Incyte Corp | Ppnqcxvhb | Ztxhs | $11.6 Bil |